key: cord-1005445-t2288a4i
authors: Saadi, N.; Chi, Y.-L.; Ghosh, S.; Eggo, R. M.; McCarthy, C.; Quaife, M.; Dawa, J.; Jit, M.; Vassall, A.
title: Models of COVID-19 vaccine prioritisation: a systematic literature search and narrative review
date: 2021-06-28
journal: nan
DOI: 10.1101/2021.06.21.21259104
sha: 8f62b054640c0d31fa6499c3a8fbaeacfd406027
doc_id: 1005445
cord_uid: t2288a4i

Background: How best to prioritise COVID-19 vaccination within and between countries has been a public health and an ethical challenge for decision-makers globally. We systematically reviewed epidemiological and economic modelling evidence on population priority groups to minimise COVID-19 mortality, transmission and morbidity outcomes. Methods: We searched the National Institute of Health iSearch COVID-19 Portfolio (a database of peer-reviewed and pre-print articles), Econlit, the Centre for Economic Policy Research and the National Bureau of Economic Research for mathematical modelling studies evaluating the impact of prioritising COVID-19 vaccination to population target groups. We narratively synthesised the main study conclusions on prioritisation and the conditions under which the conclusions changed. Findings: The search identified 1820 studies. 36 studies met the inclusion criteria and were narratively synthesised. 83% of studies described outcomes in high-income countries. We found that for countries seeking to minimise deaths, prioritising vaccination of senior adults was the optimal strategy and for countries seeking to minimise cases the young were prioritised. There were several exceptions to the main conclusion, notably reductions in deaths could be increased, if groups at high risk of both transmission and death could be further identified. Findings were also sensitive to the level of vaccine coverage. Interpretation: The evidence supports WHO SAGE recommendations on COVID-19 vaccine prioritisation. There is however an evidence gap on optimal prioritisation for low- and middle- income countries, studies that included an economic evaluation, and studies that explore prioritisation strategies if the aim is to reduce overall health burden including morbidity.

As of June 2021, over 1.5 billion vaccine doses have been administered, but vaccines are still in limited supply in the short to medium term in the vast majority of countries. [1] The question of which groups should be prioritised for vaccination within countries and between them has continued to present both a public health and an ethical challenge to decision makers. [2] The World Health Organisation (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) working group on COVID-19 vaccines has provided guidance to countries on the prioritisation of groups for vaccination while supply is limited. The guidance, based on the WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccines, seeks to ensure equitable protection of human health across the globe, and in particular, among those experiencing the greatest risk and burden of COVID-19. [2, 3] Epidemiological and economic models can provide an assessment of the potential health and broader societal impact of different prioritisation policies, and identify the optimal groups to prioritise for vaccination, given different public health objectives and scenarios. These results can be considered alongside other decision criteria to allocate vaccines both globally and within countries faced with a limited supply.

There was only a limit set of modelling results available to inform SAGE decision making at the end of 2020 (Figure 1 ), but in early 2021 the evidence base greatly expanded. The model results available at that time were largely limited to high-income and high-transmission . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104 doi: medRxiv preprint settings such as the United States of America (USA) and United Kingdom (UK). Models specifically addressing low-and middle-income countries as well as low-transmission settings were not available.

We aimed to systematically review the epidemiological and economic modelling literature on population groups to prioritise for COVID-19 vaccination to minimise COVID-19 mortality, transmission and morbidity outcomes, in order to inform prioritisation policy at both the global and national levels. Our study is structured around the policy questions that SAGE considered in 2020. In summary, these questions examined exploring optimal allocation by age groups, occupational groups, groups with comorbidities and groups at higher risk of infection, considering the impact on deaths, cases, morbidity and economic outcomes. [3] 

The systematic literature review was performed in line with PRISMA guidelines (Figure 2 ). [4] We searched the National Institute of Health (NIH) iSearch COVID-19 Portfolio on the 3 rd of March 2021 (a database which sources peer-reviewed articles from Pubmed and preprints from arXiv, bioRxiv, ChemRxiv, medRxiv, Preprints.org, Qeios, Research Square, and SSRN). We searched Econlit on the 3 rd of March 2021, using the advanced filters to include studies published between 2020 and 2021. To search these databases, we used a Boolean ra eg o combine ke ord ch a model* , acc* , econom* , co and COVID-19 . We con ac ed he Cen re for Economic Polic Re earch in the United Kingdom and the National Bureau of Economic Research in the United States and received . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104 doi: medRxiv preprint their full datasets of studies on the economics of COVID-19. (See Table S1 for the full search strategy and further details).

We included English language studies that used mathematical modelling to assess the impact of prioritising population target groups (either within or between countries) for COVID-19 vaccination on mortality, health (e.g. cases, quality adjusted life years), health care (e.g. hospitalisations) and/or economic (e.g. costs and cost-effectiveness) outcomes. We excluded studies which did not use a mathematical model to project the impact of COVID-19 vaccination, where none of the parameters were determined by empirical data (e.g. theoretical, non-empirical models), or which modelled vaccination outcomes within a clinical trial or a within-country small local setting, such as a care home, rather than nation or district wide allocation.

Two researchers independently screened titles and abstracts during the first round of screening. During the second round, three researchers independently screened titles/abstracts and full text articles. All studies were screened by at least two reviewers; where there were disagreements about inclusion these were resolved in discussion with a fourth researcher.

Three groups of two researchers each independently extracted the data from the included studies, with at least two groups reviewing each study. Discordant entries between the sets of extraction sheets were resolved by discussion between the groups. Data were recorded in Microsoft Excel files summarising the policy objectives, outcomes, characteristics of the studies, the study conclusions and the conditions under which the conclusions changed i.e. sensitivity analyses (see supplementary materials to download the full extraction sheet).

Studies explored the optimal prioritisation strategy based on different policy objectives/ outcomes (deaths, cases etc.). We therefore extracted data and organised our results tables by the objective used. Some studies used two objectives to inform prioritisation (for example cases and deaths). In this instance we extracted and synthesised both sets of results. A full list of objectives of the included studies can be found in Table 1 .

We referred to he Economic and Social Re earch Co ncil g idance on he cond c of narrative synthesis to aid data synthesis. [5] We therefore organised and grouped the textual results of the studies so that we could identify patterns within and between them. Synthesis was organised by the outcomes being explored. Due to wide variation between the studies in age group boundaries and other group classifications, extracted data from the study conclusions on vaccination priority groups were re-classified into broader population categories to aid synthesis. The population group categories considered were multi-region or not specified, using World Bank classifications for 2021. [6] We extracted the modelling methods used, and reviewed assumptions and model structure in detail for the studies that did not align with the majority of conclusions to identify if this was based on an exceptional method (referred to as e cep ion ). We also report where sensitivity analyses generated results that were contrary to main findings of the study.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104 doi: medRxiv preprint [20] , and six studies recommended vaccinating seniors at the same time as another priority group (middle-aged adults, the highest social contact group, young and middle-aged adults who are in high contact with them, young adults with partial vaccine dose, and health workers). [ 

Ten studies did not find that prioritising the groups at highest risk of mortality (seniors or people living with comorbidities) minimised deaths. [ [34] These e cep ional studies instead found that prioritising groups with a higher risk of infection would lead to fewer deaths; in other words, that the indirect protection from lower transmission outweighs the benefits from direct protection from vaccines for those at the highest risk of mortality. The group at high risk of infection were defined as those with: higher contact rates e.g. synthetic population with 3-10 times the average number of contacts of the age group 30-39 [23] ; individuals with an expansive social network [31] [32] ; and individuals with essential worker status. [27] [28] In addition, two studies defined young adults as the group with the highest social interactions and therefore at higher risk of infection. [29] [33] One study examined vaccination of individuals that had high levels of interaction with seniors. [24] . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104 doi: medRxiv preprint One of the ten exceptional studies concluded that the non-vulnerable group should be prioritised for vaccination compared to the group with comorbidities. [30] In this study the authors state they assumed ha he ime req ired o accina e he lnerable gro p i identical to that of the much larger non-lnerable gro p , e en ho gh he non-vulnerable group was much larger. Finally, one study recommended prioritising vaccination through the use of serological testing to achieve the greatest reduction in COVID-19 related deaths. [35] Prioritisation to minimise COVID-19 cases Table 3 summarises the study conclusions. The largest proportion of the selected studies (N=23) investigated optimal vaccine prioritisation strategies to minimise COVID-19 cases.

Of these, six studies recommended young and middle aged adults, [ [17] one young adults, [33] and two young adults and children. [21] [26] One study recommended young people at the same time as another priority group (seniors at full vaccine dose and young adults at partial dose). [25] Seven studies recommended vaccination prioritisation based on social or occupational interactions compared to age group prioritisation. [ Two studies recommended prioritising vaccination using serological testing to prioritise antibody-negative individuals compared to not using serological testing, [35] [38] and a . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104 doi: medRxiv preprint further study recommended that the geographic area with lower disease burden should be prioritised for vaccination compared to the geographic area with high disease burden. [39] There were a few studies concluding differently to the majority recommendations on minimising cases. Three studies found that scenarios targeting seniors [13] [18] [25] led to the highest reduction in cases. However, two of those studies did not have a comparator that modelled those strategies comparted to more socially interactive populations. [18] [25] Chhetri et al found very small differences between scenarios, and the conclusion was not reported in the results section. [13] Prioritising other outcomes [32] One study recommended prioritising vaccination by serological testing compared to no serological testing. [38] One study recommended giving equal priority to all age and risk groups compared to a targeted agebased prioritisation. [40] . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021. A few studies investigated the optimal vaccination strategy when maximising QALYs, DALYs or YLLs. One study modelled the vaccination prioritisation strategy to minimise QALY losses. [11] The authors concluded that the most effective strategy to minimise QALY losses is to prioritise senior adults for vaccination compared to other age groups, groups with comorbidities and no group prioritisation. Three studies investigated within-country vaccine prioritisation strategies for minimising YLLs. [12] [28] [22] Two studies recommended prioritising seniors for vaccination to minimise YLLs [12] [28] and the other recommended prioritising middle aged adults and seniors. [22] One study modelled the impact of COVID-19 vaccination on DALYs. [19] The authors found that the amount of DALYs averted under a base vaccination strategy which prioritised seniors was stable to a scenario where everyone over 15 years old is vaccinated. [19] One study considered the cost-effectiveness of COVID-19 vaccination. [19] The authors found that the strategy of prioritising seniors for vaccination was similarly cost-effective to vaccinating all individuals over 15 years old. [19] One study investigated prioritisation strategies for optimising the incremental net monetary benefit (iNMB) of vaccination, i.e. the net economic gain from vaccination including both costs saved and monetised health gains. [40] The authors concluded that giving equal priority to all age and risk groups was most optimal compared to prioritising seniors, high risk individuals, and both seniors and high risk individuals when vaccine effectiveness was only moderate (40%) and coverage was low (20%). Conversely, when vaccine effectiveness was high (80%) and coverage was moderate (50%), vaccinating high risk individuals resulted in the highest iNMB.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104 doi: medRxiv preprint

Three of the included articles were single-country studies modelling LMIC settings. [14] [17] [19] One study modelled an UMIC setting. [33] These studies reached the same conclusions as the HIC studies apart from one: those minimising deaths recommended prioritising seniors, while those minimising cases recommended prioritising high transmission groups.

The exception was one study from Thailand on minimising cases which recommended prioritising high transmission groups to minimise deaths. [33] Additionally, there were three multi-country studies which modelled LMIC settings [8] [9] [12] and one modelling an UMIC setting. [23] The conclusions for these studies were in line with the majority conclusions for deaths and cases (except for one study which recommended prioritising both the high social contact group and seniors to minimise deaths). [23] See Table   S5 for a summary of the studies modelling UMIC and LMIC settings.

One study also considered prioritisation between countries, in addition to within countries.

This study made recommendations on global vaccine allocation strategies to optimise different health objectives. [9] The authors concluded that the strategy to minimise deaths was to allocate doses equitably across all income settings relative to population size, and then to prioritise vaccination of seniors within countries. This performed better than allocating vaccines to countries based on their respective senior population sizes, giving preferential allocation to HICs, giving preferential allocation to LICs and LMICs, or allocating doses in proportion to population plus providing a set number of extra doses to HIC and UMICs. [9] . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104 doi: medRxiv preprint When YLLs were used as an optimisation outcome measure, LMIC settings received the most doses. Several studies tested different values of vaccine efficacy, with most reporting before full results of vaccine trials became available starting in late 2020. Generally, variations in vaccine efficacy did not appear to change prioritisation unless efficacy was significantly . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104 doi: medRxiv preprint lower in older rather than younger populations. However, a number of studies assumed that vaccines had similar levels of efficacy against severe disease, infection or transmission.

Where vaccines were more efficacious against severe disease strategies, the priority was to vaccinate highest transmitters.

We find that for countries seeking to minimise deaths, the current evidence base supports prioritising vaccination of senior adults (65+) as the optimal strategy, unless there are exceptional cases where specific non-age-related high-risk groups or very highly networked individuals can be identified and prioritised. The difference in deaths averted can be large between depending on the strategies, for example in one study, a symptom-blocking vaccine with 50% uptake prioritising seniors and high-risk groups averted 17000 more deaths than an unprioritized campaign. [20] For countries seeking to minimise cases, the evidence supports prioritising young age groups and essential workers. The evidence base examining the optimal strategy to improve health in general is too limited to draw any firm conclusions.

While in principle prioritising highly socially connected groups may be optimal to reduce mortality, it could prove difficult in practice to identify these groups, especially when their definition and identification are only vaguely defined. [31] [32] [24] [23] Chen et al. suggest those population groups could be identified through contact tracing, although recognising the limitations of such an approach in resource constrained settings. [23] Santini recommends prioritising younger people with many connections to vulnerable people. [24] Buckner et al.

find that prioritising essential workers (based on occupation) could lead to fewer deaths in the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104 doi: medRxiv preprint context of strong non-pharmaceutical interventions. [28] As no studies included the feasibility and costs of identifying and delivering vaccines to highly-connected groups, it is unclear whether prioritisation to groups that are not age or occupation-based is possible or cost-effective.

Luangasanatip et al. examined how vaccines may be prioritised in a low-incidence setting (Thailand). [33] finding that prioritising younger age groups would lead to greater reductions in deaths. However, this was the only study set in a low incidence setting, so more research may be required to validate this finding across settings and modelling approaches. The small number of studies set in low-and middle-income countries, and the lack of evidence on the cost-effectiveness of reaching different population also limits our findings in resource constrained settings.

Although we found that most of the studies modelling these settings were in line with the conclusions from studies set in HIC for minimising deaths and cases, context may impact results, especially when very limited supply is considered. The studies based in LMIC settings assumed a higher level of vaccine supply available and level of coverage achieved than has been observed in most LMICs (see Table S5 ). Moreover, many LMICs have not yet established senior adult vaccination programmes, so targeting by age may be challenging and costly. Further research is urgently required to model the effect of different levels of supply on prioritisation in lower income settings.

There was only one study modelling inter-country allocation of vaccines, despite the political importance of this issue. [42] That one study found that doses should be allocated equally by population size if minimising deaths, and allocated preferentially to low-and middle-income . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104 doi: medRxiv preprint countries if minimising life years lost. Since this differs drastically from the current allocation of vaccine doses globally, it points to the need for further investigation and action. [9] Our review found that the optimal prioritisation strategy to pursue depends on the public health objective(s) of the decision-maker, with different conclusions depending on whether the objective is reducing cases or reducing mortality. [31] [32] The trade-offs between different objectives are a challenging ethical issue for decision-makers.

The WHO SAGE values framework for the allocation and prioritization of vaccines proposed 6 principles as the ethical basis of decisions on vaccine prioritisation: the promotion of human well-being, equal respect, global equity, national equity, reciprocity and legitimacy.

[2] Within the framework, reducing disease burden overall (and not purely the number of deaths) is a key consideration to promote human wellbeing. However, only one study considered integrated burden of disease outcomes such as QALYs that combine both morbidity and mortality in relation to prioritisation [11] , one study considered DALYs. [19] This evidence gap may be particularly limiting in settings with a younger population, such as in many low-and middle-income countries, where overall mortality may be a smaller proportion of the overall COVID-19-related burden morbidity compared to high-income countries.

Only one study considered within-country equity (such as prioritising populations that have suffered disproportionately from COVID-19 because of their socioeconomic status). [37] We also consider the few economic studies, such as economic evaluations, to represent a research gap. The choice of one vaccine strategy over another in the studies evaluated often only took into account the net health gain, yet the choice of the most appropriate vaccination strategy . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021. 

The findings of this systematic literature review have provided empirical evidence for the prioritisation of senior adults for vaccination to minimise COVID-19 deaths and young people to minimise COVID-19 transmission. However, there remain critical gaps in the evidence around strategies that reduce overall health outcomes, consider the costs of different prioritisation strategies and for low-and middle-income settings. The research gaps identified can help to guide the direction of further research on vaccination prioritisation as the pandemic continues to evolve.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Older adults not covered in Stage I.

Sociodemographic groups at significantly higher risk of severe disease or death (depending on country context) Health workers engaged in immunization delivery (routine and COVID-19).

Stage III (moderate vaccine availability, for 21-50% nat. pop.)

Remaining teachers and school staff.

Other essential workers outside health and education sectors Pregnant women Health workers at low to moderate risk of acquiring and transmitting infection Personnel needed for vaccine production and other high-risk laboratory staff.

Social/employment groups at elevated risk of acquiring and transmitting infection because they are unable to effectively physically distance (depending on country context) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 28, 2021. 1 Also includes: [21] & [22] seniors and middle aged adults, [26] seniors and health workers, [25] seniors at full dose and young adults at quarter dose, [28] young adult and middle aged essential workers, [24] seniors & young and middle aged group in high contact with them, [23] high social contact group & seniors. Other: [34] school-going youth, [35] by serology testing, [30] non-vulnerable group. *Appears twice . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104 doi: medRxiv preprint 

Available: covid19.WHO.int

SAGE al e frame ork for he alloca ion and priori i a ion of COVID-19 accina ion, World Heal h Organi a ion

Ad i or Gro p of E per (SAGE) on Immunization Working Group on COVID-19 Vaccines: Prioritized Infectious Disease and Economic Modelling Q e ion , World Heal h Organi a ion

The PRISMA a emen for reporting systematic reviews and meta-analyses of studies that evaluate healthcare in er en ion : e plana ion and elabora ion

G idance on he Cond c of Narra i e S n he i in S ema ic Re ie

Ba ch, Priori i ing COVID-19 vaccination in changing social and epidemiological land cape

Age-targeted dose allocation can halve COVID-19 accine req iremen

Modelling he alloca ion and impac of a COVID-19 accine

Alloca ion of COVID-19 Vaccines Under Limi ed S ppl

Modelling op imal vaccination strategy for SARS-CoV-2 in he UK

Model-informed COVID-19 vaccine prioritization strategies by age and ero a

Op imal Vaccination and Treatment Strategies in Reduction of COVID-19 B rden, 19 Febr ar 2021

Ra o, COVID-19 Agent-Based Model with Multi-objec i e Op imi a ion for Vaccine Di rib ion

Op imi ing SARS-CoV-2 vaccination strategies in France: Results from a stochastic agent-ba ed model

Op imal SARS-CoV-2 vaccine allocation using real-time seroprevalence e ima e in Rhode I land and Ma ach e

Comparing COVID-19 accine alloca ion ra egie in India: a ma hema ical modelling d

Op imi ing Vaccine Alloca ion o Comba he COVID-19 Pandemic

Heal h impac and co -effectiveness of COVID-19 vaccination in Sindh Pro ince, Paki an, 25 Febr ar 2021

The impac of COVID-19 vaccine timing, number of doses, and risk priori i a ion on mor ali in he US

Vaccine op imi a ion for COVID-19

Op imal Alloca ion of he Limi ed COVID-19 Vaccine Supply in South Korea

WHO accina ion pro ocol can be

Co id-19 vaccination strategies with limited resources --a model based on ocial ne ork graph , 11 Oc ober 2020

Impac of personalized-dose vaccination in Covid-19 with a limited accine ppl in a 100 da period in he U.S.A., 16 Febr ar 2021

Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, A ralia

The Op imal Alloca ion of Co id-19 Vaccine

D namic Priori i a ion of COVID-19 Vaccine When Social Di ancing i Limi ed for E en ial Worker , 06 Oc ober 2020

Ac a, COVID-19 vaccine prioritisation to the gro p i h he mo in erac ion can b an iall red ce o al fa ali ie

Op imal ime o re rn o normali : parallel use of COVID-19 accine and circ i breaker , 3 Febr ar 2021

Priori i ing alloca ion of COVID-19 vaccines based on social con ac increa e accina ion effec i ene , 16 Febr ar 2021

Op imali in COVID-19 vaccination strategies determined by heterogeneity in human-h man in erac ion ne ork

Teera a ananon, Op imal vaccine strategy to control COVID-19 pandemic in middle-income countries: Modelling ca e d of Thailand, 24 Febr ar 2021

Second-wave dynamics of COVID-19: Impac of beha ioral change , imm ni lo , ne rain , and accina ion

Significance of SARS-CoV-2 Specific Antibody Testing during COVID-19 Vaccine Alloca ion, 1 Febr ar 2021

COVID-19 Spreading Dynamics with Vaccination Alloca ion S ra eg , Re rn o Normalc and Vaccine He i anc

Schlo erbeck, De erminan of SARS-CoV-2 transmission to guide vac2 cination ra eg in a ci

Epidemiological impac of priori i ing SARS-CoV-2 vaccination b an ibod a : Ma hema ical modeling anal e

Spa ial Alloca ion of Scarce Vaccine and An i iral for COVID-19

A Ne Benefi Approach for the Optimal Allocation of a COVID-19 Vaccine

Op imal ra egie for combining accine priori i a ion and ocial di ancing o red ce ho pi ali a ion and mi iga e COVID19 progre ion

Challenge in en ring global acce o COVID-19 accine : prod c ion, affordabili , alloca ion, and deplo men

Also includes young and middle-aged adults, young adults and children. Other: [40] all age groups equally

(n)